These outcomes support our in vitro findings and indicate that SIC-19 causes DNA damage in the animal model and degrades the endogenous SIK2 protein, increasing the sensitivity of breast cancer cells to olaparib. This evidence concerns the gene SIK2 and breast carcinoma.